Background Despite encouraging results with the proteasome inhibitor bortezomib in the
treatment of hematologic malignancies, emergence of resistance can limit its efficacy, hence …

The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …

We generated eight multiple myeloma cell lines resistant to bortezomib; five acquired
PSMB5 mutations. In 1,500 patients such mutations were rare clinically. To better …

The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …

Proteasome inhibition is a novel treatment for several hematological malignancies.
However, resistance to the proteasome inhibitor bortezomib (BTZ, Velcade) is an emerging …

Variations within proteasome β (PSMB) genes, which encode the β subunits of the 20S
proteasome, may affect proteasome function, assembly, and/or binding of proteasome …

The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has
encouraged application of proteasome inhibitor containing therapeutic interventions in …

PR-924 is a novel prototypic immunoproteasome inhibitor bearing markedly enhanced
specificity for the β5i immunoproteasome subunit, compared to the classical proteasome …

Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and
Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but …

Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …